Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses...

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care Interim analysis of Phase 1B data suggests Processa’s novel chemotherapy treatment could improve safety and efficacy in more patients by individualizing the dosing regimen for each patient HANOVER,...

Quadient annonce qu’un quatrième transporteur rejoint son réseau ouvert de consignes colis au Royaume-Uni Quadient annonce qu’un quatrième transporteur rejoint son réseau ouvert de consignes colis au Royaume-Uni Paris, le 13 décembre 2022 Quadient (Euronext Paris : QDT), un opérateur majeur de consignes...

Quadient Announces Fourth Carrier Joining its Smart Locker Open Network in the UK Quadient Announces Fourth Carrier Joining its Smart Locker Open Network in the UK Paris, December 13, 2022 Quadient (Euronext Paris: QDT), a leader in helping businesses create meaningful customer...

Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine) Processa focuses on identifying the PCS6422 regimens to increase capecitabine potency while identifying the MTD of Next Generation Capecitabine The amended protocol will provide a more precise...